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Abstract
Background: Numerous studies indicate that cancer cells present an aberrant glycosylation
pattern that can be detected by lectin histochemistry. Lectins have shown the ability to recognise
these modifications in several carcinomas, namely in the prostate carcinoma, one of the most lethal
diseases in man. Thus, the aim of this work was to investigate if the α-D-galactose-binding plant
lectin frutalin is able to detect such changes in the referred carcinoma. Frutalin was obtained from
different sources namely, its natural source (plant origin) and a recombinant source (Pichia
expression system). Finally, the results obtained with the two lectins were compared and their
potential use as prostate tumour biomarkers was discussed.
Results: The binding of recombinant and native frutalin to specific glycoconjugates expressed in
human prostate tissues was assessed by using an immuhistochemical technique. A total of 20 cases
of prostate carcinoma and 25 cases of benign prostate hyperplasia were studied. Lectins bound
directly to the tissues and anti-frutalin polyclonal antibody was used as the bridge to react with the
complex biotinilated anti-rabbit IgG plus streptavidin-conjugated peroxidase. DAB was used as
visual indicator to specifically localise the binding of the lectins to the tissues. Both lectins bound
to the cells cytoplasm of the prostate carcinoma glands. The binding intensity of native frutalin was
stronger in the neoplasic cells than in hyperplasic cells; however no significant statistical correlation
could be found (P = 0.051). On the other hand, recombinant frutalin bound exclusively to the
neoplasic cells and a significant positive statistical correlation was obtained (P < 0.00001). However,
recombinant frutalin did not recognise all malignant prostate cases and, when positive, the binding
to those tissues was heterogeneous.
Conclusion: Native and recombinant frutalin yielded different binding responses in the prostate
tissues due to their differences in carbohydrate-binding affinities. Also, this study shows that both
lectins may be used as histochemical biomarkers for the prostate cancer. Moreover, the successful
use of a recombinant lectin in immunohistochemical studies of prostate cancer was for the first
time demonstrated, highlighting the advantages of using recombinant systems in the preparation of
pure lectin samples for diagnostic purpose.
Published: 9 September 2009
BMC Biotechnology 2009, 9:78 doi:10.1186/1472-6750-9-78
Received: 20 April 2009
Accepted: 9 September 2009
This article is available from: http://www.biomedcentral.com/1472-6750/9/78
© 2009 Oliveira et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2009, 9:78 http://www.biomedcentral.com/1472-6750/9/78
Page 2 of 7
(page number not for citation purposes)
Background
Prostate carcinoma is one of the most common causes of
cancer-related deaths in men older than 50 years of age. It
is predominantly a disease of older men, with a peak inci-
dence between the ages of 65 and 75 years. Although the
cause of prostate cancer is still unknown, clinical and
experimental observations suggest that hormonal,
genetic, diet and environmental factors, may play a role in
its pathogenesis [1-6]. Carcinomas of the prostate are
often clinically silent, especially during their initial stages,
thus all efforts made towards early diagnosis and thera-
peutic investigations are important for the treatment of
this malignant disease.
Cellular glycoconjugates are localised intracellularly,
extracellularly and also at the cell surface, where they can
be secretory or structural. Glycoproteins of the cell surface
play different roles in cell function including cell differen-
tiation, adhesion, proliferation, morphological changes
and functional modulation. Glycosylation plays a major
role by determining and stabilising protein folding, mod-
elling of physicochemical properties and determining cell
immunogenicity [7]. In the case of the prostate, complex
glycans are important for the functional activity of this
organ [8]. Glycoconjugates undergo modification associ-
ated with the cellular functions perform by them and also
under pathological conditions. The glycosylation profile
on tumour cells glycoproteins is distinctly different from
that on normal cells, due to the blockage of the glycosyla-
tion pathways. This phenomenon results in the incom-
plete elongation of O-glycans and premature sialylation,
leading to the expression of shorter and modified cancer-
associated oligosaccharides such as T, sialyl-T, Tn, sialyl-
Tn, LewisX (LeX) and sialyl-LeX, with a drastic impact in
the cells normal function [9,10].
Lectins are proteins of non-immune origin that reversibly
bind specific carbohydrates and that may also agglutinate
cells, precipitate polysaccharides or glycoconjugates [11].
They are widely used in biomedical diagnostic research as
histochemical probes to localise and characterise specific
carbohydrates residues or oligosaccharides in cells and tis-
sues [12]. Lectin studies conducted in the human prostate,
and in its secreted glycoproteins (e.g. PSA - prostate-spe-
cific antigen), have demonstrated their applicability as
biomarkers of specific secretory functions, structural com-
ponents and developmental alterations of this gland [13-
16]. Additionally, lectins histochemical studies were per-
formed to detect changes in glycoconjugates associated
with pre-neoplasic and neoplasic transformation of the
prostate [8,17]. Frutalin is a tetrameric jacalin-related lec-
tin expressed in the breadfruit plant seeds (Artocarpus
incisa) that specifically recognises α-D-galactose residues
[18]. Frutalin may be successfully used in immunobio-
logical research, on the recognition of cancer-associated
oligosaccharides, similarly to other galactose-binding
lectins [19]. However, the use of lectins isolated from their
natural sources presents several disadvantages, namely the
heterogeneity of the sample due to the presence of lectin
isoforms, which may lead to results variability. One way
to overcome these limitations is a recombinant expression
and production, which might improve and facilitate lectin
availability and offer a higher level of purity and control
of the lectin final properties.
In this work, the expression of frutalin specific glycocon-
jugates in human tissues of prostate carcinoma and
benign prostate hyperplasia (BPH) was studied by immu-
nohistochemistry. The binding pattern obtained with the
breadfruit frutalin and with the recombinant frutalin pro-
duced by Pichia pastoris in the prostate tissues was com-
pared and their potential use as tumour biomarkers was
evaluated. For the first time a lectin from a recombinant
source was used in immunohistochemical studies of
human prostate tissues.
Methods
Tumour tissue blocks origin
Formalin-fixed, paraffin-embedded blocks of 20 cases of
prostate carcinoma and 25 cases of BPH were analysed. All
the cases were retrieved from the files of the Institute of
Molecular Pathology and Immunology of the University
of Porto (IPATIMUP), Portugal, during the period of 2004
to 2007. The mean age of the patients with prostate carci-
noma was 64 years and of the patients with BPH was 68
years. The twenty carcinoma cases were graded according
the Gleason scoring system [20]: 18 cases were Gleason
score 7 (3+4), one case was Gleason score 6 (3+3) and
other Gleason score 8 (4+4).
Lectins production/purification and antibodies
Native frutalin was purified from A. incisa seeds as previ-
ously described [18]. The production and purification of
recombinant frutalin in the P. pastoris expression system
has previously been reported [21]. Polyclonal antibody
against native and recombinant frutalin was produced by
inoculating New Zealand rabbits with native frutalin. The
specificity of this antibody to both lectins was previously
confirmed by Western blot analysis [21]. The antibody to
rabbit IgG was "Biotinylated Goat Anti-Polyvalent", pur-
chased from LabVision Corporation (Fremont, USA).
Immunohistochemistry
The localisation of frutalin specific glycoconjugates in the
prostate tissues was carried out by using the streptavin-
biotin-peroxidase complex immunohistochemical tech-
nique. Slides were deparaffinised in xylol and rehydrated
in a graded ethanol series. The antigen retrieval was done
by incubating slides in boiling 10 mM citrate buffer (pH
6.0) for 30 min, using a microwave at 900 Watts, followedBMC Biotechnology 2009, 9:78 http://www.biomedcentral.com/1472-6750/9/78
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by cooling at room temperature for another 20 min. After
washes in PBS buffer (8 g/l NaCl, 0.2 g/l KCl, 2.68 g/l
Na2HPO4·7H2O and 0.24 g/l KH2PO4, pH 7.4 adjusted
with HCl), endogeneous peroxidase activity was inacti-
vated by incubating the slides for 10 min in 3% (v/v)
H2O2/methanol. Slides were then incubated with a block-
ing serum (LabVision Corporation, Fremont, USA) for 10
min, for blockage of non-specific protein binding, and
then incubated for 1 h at 37°C with native frutalin (1 μg/
ml) or recombinant frutalin (50 μg/ml). After washes in
PBS, the slides were incubated overnight at 4°C with pol-
yclonal anti-frutalin antibody (0.5 μg/ml). Afterwards, the
slides were washed in PBS and incubated for 10 min at
room temperature with biotinylated secondary antibody,
following by incubation with streptavidin-conjugated
peroxidase solution for another 10 min (LabVision Cor-
poration, Fremont, USA). Diaminobenzidine (DAB) was
used as the chromogen and finally, the tissues were coun-
terstained with hematoxylin and covered with a mounting
solution (Entellan). In each run a positive control (the
binding of native frutalin to a prostate carcinoma tissue)
and a negative control (where frutalin was replaced with
PBS during the lectin incubation period) were also
included. All PBS washes were conducted at room temper-
ature and each wash was done two times for 5 min.
The binding of the lectins to the prostate tissues was
revealed by a brown colour, as a result of the DAB reaction
with the streptavidin-conjugated peroxidase solution. The
staining of the tissues was assessed by one pathologist.
The frutalin binding was evaluated by the intensity of its
cytoplasmatic staining, being graded as negative (0), low
(+), moderate (++) or strong (+++), according to the liter-
ature [22].
Statistical analysis
Results were statistically analysed using the program SPSS
for windows (version 16.0). The grades of lectin binding
intensity were converted numerically as negative = 0, low
= 1, moderate = 2 and strong = 3. Mann-Whitney U anal-
ysis was used to compare the global binding intensity
obtained for each lectin in the two studied histological
groups. Results were only considered statistically signifi-
cant if P < 0.05.
The present study was conducted under the national regu-
lative law for the usage of biological specimens from
tumour banks, where the samples are exclusively available
for research purposes in the case of retrospective studies.
Results
The results of the immunohistochemical analysis
obtained for the binding of native and recombinant fruta-
lin to the human prostate tissues are summarised in Table
1. Native frutalin bound to all the studied cases of prostate
carcinoma (100%; 20/20), as well as to all the studied
cases of benign prostate hyperplasia (BPH) (100%; 25/
25). On the other hand, recombinant frutalin bound to a
part of the studied cases of prostate carcinoma (70%; 14/
20) and did not bind to any of the studied cases of BPH
(0%; 0/25). As the anti-frutalin antibody also bound to
the prostate tissues, its concentration was decreased until
no binding was observed. Additionally, negative controls
were done (where frutalin was replaced with PBS during
the lectin incubation period) to make sure that the bind-
ing responses obtained corresponded in fact to frutalin
and not to the anti-frutalin antibody.
BPH is a benign lesion of the prostate and it is character-
ised by the proliferation of both epithelial and stromal
elements, with resultant enlargement of the gland (e.g.
Figure 1A). The prostate carcinomas are composed of
small glands that infiltrate the adjacent stroma in an irreg-
ular, haphazard fashion (e.g. Figure 1D). In contrast to
normal and hyperplasic prostate glands, the glands in car-
cinomas are not encircled by collagen or stromal cells but
rather lie "back to back" and appear to dissect sharply
though the native stroma. The neoplasic glands are lined
by a single layer of cuboidal cells with conspicuous nucle-
oli and the basal cell layer seen in normal or hyperplasic
glands is absent. Native frutalin bound to the cells cyto-
plasm of both carcinoma (Figure 1F and 1H) and benign
prostate hyperplasic glands (Figure 1B). The native fruta-
lin binding pattern was found to be homogeneous in all
situations. Frutalin specific sugars were also often detected
in the stroma of some malignant prostate tissues (data not
shown). As mentioned above, recombinant frutalin did
not bind to the benign prostate hyperplasic tissues (Figure
1A). As native frutalin, recombinant frutalin bound to the
cells cytoplasm of the carcinoma glands (Figure 1C, E and
Table 1: Immunohistochemistry results for the binding of native and recombinant frutalin to human prostate tissues
Histological diagnosis Native frutalin Recombinant frutalin
n positive % n positive %
Benign prostate
hyperplasia
25/25 100 0/25 0
Prostate
carcinoma
20/20 100 14/20 70BMC Biotechnology 2009, 9:78 http://www.biomedcentral.com/1472-6750/9/78
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Detection of frutalin specific glycoconjugates expressed in sections of human prostate tissues by immunohistochemistry Figure 1
Detection of frutalin specific glycoconjugates expressed in sections of human prostate tissues by immunohisto-
chemistry. Samples of formalin-fixed, paraffin-embedded tissues from benign prostate hyperplasia (A, B) and prostate carci-
noma (C to H) were immunostained with recombinant frutalin (A, C, E, G) and native frutalin (B, F, H). A negative control 
proves that the binding responses observed in the prostate carcinoma tissues corresponded to the lectins (D). No detectable 
recombinant frutalin binding was observed in hyperplasic cells (A), while weak staining was detected for native frutalin (B). 
Both lectins bound to cytoplasm cells of carcinoma glands (C, E, F, G and H, shown by the white arrows). The binding of 
recombinant frutalin to the carcinoma tissues was heterogeneous, with closed glands having strong and weak staining (C). The 
native frutalin staining was strong and homogeneous in carcinoma glands (F and H). Recombinant frutalin was able to specifi-
cally recognise carcinoma cells in middle of a benign lesion (E and G).
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1G). The recombinant frutalin binding pattern was heter-
ogeneous, with closed glands having strong and weak
staining (Figure 1C), as well as positive and negative areas
throughout the tissues.
The statistical analysis of the intensity score of the native
and recombinant frutalin binding to the prostate tissues is
shown in Table 2. The majority of the malignant cases had
a strong native frutalin binding (60%; 12/20), while the
benign cases presented mostly a moderate binding for this
lectin (52%; 13/25). In spite of decreased intensity of the
native frutalin binding in hyperplasic cells, compared to
carcinoma cells, no significant correlation was found (P >
0.05). Recombinant frutalin binding to malignant cases
was mainly low or moderate (65%; 13/20) and did not
occur in the benign cases (0%; 0/25). A significant posi-
tive association was found between the intensity of the
recombinant frutalin binding and the tissues histology (P
< 0.00001). Since the majority of cases were Gleason 7
and they are distributed along all different intensities of
reactions of native and recombinant frutalin staining, we
do not find any association between Gleason scoring sys-
tem and intensity of staining for both lectins.
Discussion
The major sugar residues present in the oligosaccharides
of the cell surfaces glycoconjugates are: mannose, N-
acetylglucosamine (GlcNac), N-acetylgalactosamine (Gal-
Nac), galactose (Gal), fucose (Fuc), and derivatives of
sialic acid. The distinct property of lectins to bind specific
carbohydrates makes them capable of recognising certain
cell surface glycoproteins and detecting alterations on
that, by using histochemical techniques. Various lectins
have been used as biomarkers of human tumours, on the
differentiation of dysplasic/neoplasic cells from normal/
hyperplasic cells, as well as on the screening and progno-
sis of different types of carcinomas.
Several studies have shown that cell transformation into
malignancy is closely related to an abnormal expression
of carbohydrates on cell surfaces. A lectin immunohisto-
chemical study suggested a strong expression of N-acetyl-
galactosamine residues in BPH and an increased
expression of galactose, fucose and sialic acid residues in
prostate carcinoma [8]. Thus, it would be expected that
the galactose-binding lectin frutalin would recognize
these modifications. Nevertheless, significant differences
were found between the binding pattern of native and
recombinant frutalin in the prostate tissues. Native fruta-
lin bound to both hyperplasic and carcinoma tissues,
while recombinant frutalin only bound to carcinoma tis-
sues. However, the binding of recombinant frutalin to the
neoplasic tissues was heterogeneous and did not occur in
all studied cases. On the other hand, the binding of native
frutalin was homogenous in all cases and very intense in
the malignant ones. We have recently reported that native
and recombinant frutalin presented a difference of at least
120-fold in carbohydrate-binding affinity [21]. The two
lectins showed similar sugar-binding specificity but
recombinant frutalin demonstrated less affinity. Thus, it
can be concluded that it is the distinct carbohydrate-bind-
ing affinity presented by these two lectins that would lead
to the different binding responses obtained. This is
explained by the molecular differences found between
native and recombinant frutalin [21]. Both are tetramer
glycoproteins, but native frutalin is made of cleaved α and
β chains, while in recombinant these two chains are con-
nected by a linker tetrapeptide, because the cleavage of
this linker did not occur in the P. pastoris expression sys-
tem. It has already been reported that the linker cleavage
may be needed to improve sugar-binding affinity of galac-
tose-binding jacalin-related lectins [21,23]. Moreover, the
Pichia glycosylation pattern possibly altered the biological
activity of recombinant frutalin as it inhibited the ability
to agglutinate rabbit erythrocytes. In this study, recom-
binant frutalin has unequivocally distinguished between
benign and malignant cells, binding exclusively to the
neoplasic cells, in contrast to native frutalin. Thus, it can
be concluded that the putative diagnostic value of recom-
binant frutalin may be higher than that for the native lec-
Table 2: Statistical analysis of the binding intensity of native and recombinant frutalin in human prostate tissues
Frutalin/source Histological diagnosis Number of cases for each binding intensity* Mann-Whitney U analysis
0 + ++ +++ Mean Rank P
Native
(A. incisa)
Benign prostate hyperplasia 0
(0%)
4
(16%)
13
(52%)
8
(32%)
19.90 0.051I
Prostate carcinoma 0
(0%)
1
(5%)
7
(35%)
12
(60%)
26.88
Recombinant
(P. pastoris)
Benign prostate hyperplasia 25
(100%)
0
(0%)
0
(0%)
0
(0%)
16.00 0.000S
Prostate carcinoma 6
(30%)
9
(45%)
4
(20%)
1
(5%)
31.75
*The binding intensity was converted numerically as: negative (0) = 0, low (+) = 1, moderate (++) = 2 and strong (+++) = 3; I Insignificant statistical 
result; S Significant statistical result.BMC Biotechnology 2009, 9:78 http://www.biomedcentral.com/1472-6750/9/78
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tin. Native frutalin recognised all different histological
prostate tissues possibly due to its higher carbohydrate-
binding affinity and broad carbohydrate-binding range.
In fact, native frutalin is a poly-specific lectin, as showed
by sugar-binding fluorescence studies [21]. Native frutalin
strongly reacted with the T-antigen disaccharide (Galβ1,
3GalNac) (binding constant in the 104 M-1 range) while
no binding was observed with the recombinant frutalin.
Furthermore, the affinity of recombinant frutalin to the
monosaccharide Me-α-galactose is in the same magnitude
order of the native frutalin affinity to other sugars that
recombinant lectin did not recognise, as is the case of D-
glucose (binding constants in the 102 M-1 range). There-
fore, the binding of frutalin to specific cancer-associated
oligosaccharides could have been masked in prostate car-
cinoma tissues by the presence of other frutalin binding
sugars. Nevertheless, the native frutalin binding responses
suggest an increased expression of α-D-galactose residues
on the neoplasic cells surface, as its binding was generally
more intense in neoplasic cells than in hyperplasic cells,
which corroborates previous studies [8].
Several lectins have been used in histochemical studies of
the human prostate, to detect glycoconjugate changes
related with the malignant transformation of this gland.
The most studied lectins were the plant lectins soybean
agglutinin (SBA - Glycine max agglutinin, specificity:
α,βGal, α,βGalNAc) [8,24-28], the gorse (furze) aggluti-
nin (UEA-I - Ulex europaeus agglutinin, specificity: α-L-Fuc,
GlcNAcβ1, 4GlcNAc) [8,24,26-30], and the peanut agglu-
tinin (PNA - Arachis hypogaea agglutinin, specificity:
Galβ1,3GalNAc) [8,17,24,26-28,31], which present dif-
ferent carbohydrate-binding specificities. Lectins from
other organisms were also studied, such as the animal lec-
tin HPA (garden snail - Helix pomatia agglutinin, specifi-
city: αGalNAc, αGlcNAc, αGal) [8] and the fungal lectin
AAL (mushroom - Aleuria aurantia lectin, specificity: α-L-
Fuc) [8,32]. Namely, several studies have demonstrated
that the expression of HPA-binding glycoproteins on var-
ious human cancers, such as prostate carcinoma, is a
marker of metastatic potential and poor prognosis [32].
The plant lectins SBA, UEA-I and PNA, as recombinant
and native frutalin, were able to differentiate cells from
distinct prostate histological tissues. Namely, SBA and
UEA-I showed to be useful indicators of the prostate
malignancy, as they distinguished between benign and
malignant prostate cells, binding exclusively to dysplasic/
carcinoma cells [24,27,28], or binding stronger to these
cells, comparing to normal/hyperplasic cells binding
[8,26,30]. However, in some studies SBA could not distin-
guish the referred cells [25,26]. In addition, the PNA lectin
bound stronger to neoplasic cells than to normal and
hyperplasic cells [8,17,26,27]. Nevertheless, negative
binding in some malignant cases was also reported for
these lectins, namely for the T-antigen specific PNA lectin
(16% of total cases) [31].
It should be noted that all these lectins were obtained
from their natural sources and therefore their availability
is dependent from a time-consuming process and the final
properties can vary as a result of different "batch to batch"
isolations. This might have contributed to the variable
and contradictory results above described. Frutalin, in
particularly, is a heterogeneous mixture of several slightly
different amino-acid sequences (isoforms), having or not
different glycosylation places and extensions, while
recombinant frutalin has a defined amino-acid sequence
and therefore its properties are more effective. Frutalin
isoforms may have different sugar-binding specificities/
affinities and, consequently, variable results can be
obtained. Furthermore, recombinant frutalin can be easily
produced and purified in the P. pastoris heterologous
expression system, which is an excellent way for frutalin
large-scale production, considering its diagnostic applica-
tion.
Conclusion
In this work, the binding of the frutalin lectin, obtained
from its natural source and from a recombinant system, to
prostate tissues was studied by immunohistochemistry.
The results demonstrated that there are alterations in the
carbohydrates of cellular glycoconjugates of benign and
malignant human prostate tissues, detected by recom-
binant and native frutalin, namely enhancement of galac-
tose residues in malignancy. The carbohydrate-binding
properties of each lectin were responsible for the different
binding patterns observed. Native frutalin bound stronger
to neoplasic cells than to hyperplasic cells, while recom-
binant frutalin specifically recognised malignant cells.
This study shows that both lectins have a considerable
potential value in differentiating neoplasic changes from
benign lesions of the human prostate. Namely, recom-
binant frutalin may be a useful tool to elucidate cases of
difficult diagnosis. Moreover, the use of the P. pastoris
recombinant system for frutalin production is more
advantageous than the use of natural sources as the pro-
duction and purification methodologies are easier and
pure homogeneous frutalin samples are obtained.
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